Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
ART.ASAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the launch of its DIRECT-AI registry study. This study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer. Additionally, the study will monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera's commitment to advancing perso
June 17, 2025Clinical Trials
Read more →